Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 66

Results For "United-States"

841 News Found

Pfizer to acquire Biohaven Pharmaceuticals for US $ 11.6 billion
Biotech | May 10, 2022

Pfizer to acquire Biohaven Pharmaceuticals for US $ 11.6 billion

Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need


Glenmark receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate
Drug Approval | May 09, 2022

Glenmark receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate

Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA


USFDA limits use of J&J Covid-19 vaccine to certain individuals
News | May 06, 2022

USFDA limits use of J&J Covid-19 vaccine to certain individuals

The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible


Lupin receives USFDA approval for Pregabalin and Iloperidone
Drug Approval | May 06, 2022

Lupin receives USFDA approval for Pregabalin and Iloperidone

While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility


Zydus receives tentative approval from USFDA for Selexipag tablets
Drug Approval | May 06, 2022

Zydus receives tentative approval from USFDA for Selexipag tablets

The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad


Merck invests $110 million to expand production site in China
News | May 05, 2022

Merck invests $110 million to expand production site in China

Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities


Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets including India
Biotech | May 04, 2022

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets including India

Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication


Xcardia announces first-in-human use of its new Xtractor device
Biotech | May 02, 2022

Xcardia announces first-in-human use of its new Xtractor device

The announcement follows FDA 510(k) clearance of device


Tislelizumab plus chemo show promising results for esophageal cancer in Phase III study
Biotech | April 27, 2022

Tislelizumab plus chemo show promising results for esophageal cancer in Phase III study

Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours


Biocytogen signs RenMab/RenLite licensing agreement with BeiGene
Biotech | April 26, 2022

Biocytogen signs RenMab/RenLite licensing agreement with BeiGene

In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)